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Naturally occurring CD25+CD4+ regulatory 
T cells (T reg cells) are currently intensively 
characterized because of their major importance 
in modulating host responses to tumors and 
infections, in preventing transplant rejection, 
and in inhibiting the development of auto-
immunity and allergy (1–3). Originally, CD4+ 
T reg cells were identifi  ed exclusively by the 
constitutive expression of CD25, and many 
in vivo experiments have been performed us-
ing depleting antibodies directed against CD25 
(4, 5). However, both the existence of CD25− 
T reg cells, especially within peripheral tissues 
(1, 6, 7), as well as the expression of CD25 on 
activated conventional T cells, which precludes 
discrimination between T reg cells and acti-
vated conventional T cells, limits the interpre-
tation of data obtained by the use of anti-CD25 
depleting antibodies (7–9). The most specifi  c 
T reg cell marker currently known is the fork-
head box transcription factor Foxp3, which 
has been shown to be expressed specifi  cally in 
mouse CD4+ T reg cells and acts as a master 
switch in the regulation of their development 
and function (10). Moreover, activated con-
ventional mouse CD4+ T cells or diff  erentiated 
Th1/Th2 cells fail to induce Foxp3 expression 
(11, 12).
A key role of Foxp3 in the development of 
natural T reg cells has been suggested from the 
molecular characterization of the scurfy mouse 
mutant. These mice, which suff  er from a fatal 
lymphoproliferative disorder, harbor a mutated 
foxp3 gene coding for a product that lacks the 
forkhead domain (13). Scurfy mice receiving 
CD25+CD4+ T reg cells from WT mice re-
mained virtually disease free (11). Furthermore, 
transduction of mutant Foxp3, lacking the fork-
head domain, failed to confer suppressive activity 
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mental evidence that the absence of Foxp3+ T reg cells is indeed suffi  cient to induce a 
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the function of Foxp3+ T reg cells in immune reactions in vivo.
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to naive CD4+ T cells, in contrast to full-length Foxp3 (12). 
Thus, it is widely accepted that an intrinsic T cell failure 
to generate functional CD4+ T reg cells is the main cause of 
the fatal autoimmune disease in scurfy mice, although an 
  additional role of the scurfy mutation in nonhematopoietic 
cells has been suggested (14, 15). Moreover, it remains un-
known whether the mere absence of functional Foxp3+ 
T reg cells is suffi   cient to provoke the development of the 
scurfy phenotype or whether those CD4+ T cells expressing 
the truncated Foxp3 protein play a more active role, because 
depletion of T reg cells with established protocols has failed 
to reproduce the fulminant natural disease (4, 5). The latter 
hypothesis is supported by the fact that scurfy disease could 
be transplanted into nude mice through adoptive transfer of 
CD4+ T cells (16). Furthermore, Foxp3+ T reg cells prefer-
entially recognize self-antigens with high affi   nity (17, 18), 
and activated, not naive, T cells in Foxp3-defi  cient mice 
preferentially use TCRs found in the TCR repertoire of 
T reg cells in Foxp3-suffi   cient mice (19). Collectively, these 
data led to the hypothesis that these “would-be” T reg cells 
expressing self-reactive TCRs may contribute to the patho-
logy of Foxp3-defi  cient mice (19).
To address the question of the in vivo role of T reg cells 
in immunopathology, we have generated bacterial artifi  cial 
chromosome (BAC)–transgenic mice termed “depletion of 
regulatory T cell” (DEREG) mice, which express a diphthe-
ria toxin receptor (DTR) enhanced GFP (eGFP) fusion pro-
tein under the control of the foxp3 locus, allowing both 
detection and inducible depletion of Foxp3+ T reg cells. 
Phenotypic characterization of DEREG mice not only re-
vealed an eGFP expression pattern similar to that of previ-
ously published Foxp3 reporter mice (20, 21) but also showed 
that DT treatment, in contrast to conventional T reg cell 
  depletion strategies, allows for effi   cient and selective deple-
tion of Foxp3+ cells without aff  ecting CD25+ eff  ector T cells. 
  Interestingly, ablation of Foxp3+ T reg cells in newborn 
DEREG mice led to the development of scurfy-like symp-
toms, thus providing direct evidence that Foxp3+ T reg 
cells are critically involved in controlling homeostasis of the 
immune system and in preventing the development of auto-
immune diseases.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
Generation of BAC-transgenic DEREG mice
BACs are large fragments of genomic DNA cloned into 
bacterial vectors that allow for stable propagation in bacteria. 
Given the large size of BACs, most if not all regulatory 
sequences of a gene are present and can be used to direct 
faithful and tissue-specifi  c expression of heterologous genes 
in vivo in BAC-transgenic mice. We modifi  ed a BAC con-
taining the foxp3 locus by introducing the gene coding for a 
DTR-eGFP fusion protein into the fi  rst exon of the foxp3 
gene (Fig. 1 A). The modifi  ed 150-kb BAC was injected 
into the pronuclei of fertilized C57BL/6 oocytes. Transgenic 
mouse lines with high transgene expression were established. 
The transgenic mice were termed DEREG mice. Analysis 
of DEREG mice revealed selective DTR-eGFP expression 
within the CD4+ T cell compartment, with the highest ex-
pression within the CD25+ subset (Fig. 1 B). Importantly, 
similar frequencies and total numbers of CD25+CD4+ T reg 
cells were observed between DEREG and WT mice (Fig. 
1 C and not depicted), and Foxp3 levels in CD25+CD4+ 
T reg cells from DEREG mice were comparable to T reg 
cells from WT mice (Fig. 1 D), ruling out the possibility 
that the BAC transgene infl  uences regulation of the endo-
genous foxp3 locus. Histological and fl  ow cytometry analysis 
of spleen, thymus, and LN revealed that the BAC transgene, 
Figure 1.  DEREG mice specifi  cally express DTR-eGFP in T reg cells. 
(A) Map of BAC construct used for generation of transgenic mice. I and XI 
indicate the positions of exons I and XI of the foxp3 gene. 24 bp of exon I 
were replaced by the gene coding for DTR-eGFPpA by homologous 
re  combination with a 1-kb 5′ and 3′ homologous sequence (Boxes A and B). 
(B) Transgene expression is specifi  c for CD25+CD4+ T cells in naive DEREG 
mice. Flow cytometric analysis of live-gated CD4+ LN cells of the indi-
cated genotype reveals GFP expression mainly in CD25+CD4+ T cells. 
(C) Analysis of CD25+CD4+ T cell subsets in LNs from DEREG mice and WT 
littermates. Plots show similar frequencies of the cell subset in live-gated 
cells. (D) Foxp3 and GFP expression of LN cells. Flow cytometric analysis 
reveals a specifi  c transgene expression in T reg cells. Cells are live gated. 
The percentage of cells in each quadrant (B–D) is indicated.JEM VOL. 204, January 22, 2007  59
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encoding the DTR-eGFP fusion protein, is faithfully ex-
pressed in Foxp3+CD4+ T cells and is absent from thy-
mic epithelial as well as B220+ and CD8+ cells (Fig. 2 and 
Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20061852/DC1). Furthermore, no gross alteration in the 
frequency and total number of CD4+ and CD8+ T cells, 
B220+ B cells, and CD11c+ DCs was observed in LNs and 
spleen of DEREG mice when compared with WT controls 
(Fig. S1 and not depicted). In addition, CD25+CD4+ T reg 
cells from DEREG and WT mice displayed a similar in vitro 
suppressive capacity (not depicted). Collectively, DEREG mice 
showed specifi  c expression of the DTR-eGFP fusion protein 
in fully functional Foxp3+CD4+ T reg cells.
DT injection allows selective depletion of Foxp3+ T reg cells
Next we assessed whether injection of DT leads to selective 
depletion of Foxp3+ T reg cells in vivo. To achieve this, 
6-wk-old DEREG mice were injected with 1 μg DT per 
mouse for six consecutive days. On day 7, we analyzed Foxp3 
expression in various lymphoid organs. Among splenocytes 
and LN-derived cells, we observed an almost complete oblit-
eration in the frequency and absolute number of Foxp3+CD4+ 
Figure 2.  Localization of Foxp3+ cells in the spleen and thymus. 
(A) Spleen sections were stained with αB220-allophycocyanin (blue), 
αCD3–Alexa Fluor 555 (red), and αGFP–Alexa Fluor 488 (green). (B) Thymus 
sections were stained with αCD3–Alexa Fluor 647 (blue), αFoxp3–Alexa 
Fluor 555 (red), and αGFP–Alexa Fluor 488 (green). Bars: (A and B, left) 
500 μm; (A, right) 100 μm; (B, right) 50 μm.
Figure 3.  Depletion of Foxp3+ cells with DT in DEREG mice. After six 
consecutive days of DT injection (1 μg/day), mice were killed on day 7, and 
lymphoid organs were removed. (A) Flow cytometric analysis of LN-derived 
cells and splenocytes shows effi  cient depletion of Foxp3+ cells in 
DT-treated DEREG mice compared with DT-treated WT control mice. The per-
centage of cells in each quadrant is indicated. (B) Foxp3 staining (brown) of 
thymic and Peyer’s patch (PP) sections shows effective depletion of Foxp3+ 
cells in DT-treated compared with untreated DEREG mice. Bar, 100 μm.60  INDUCED SCURFY PHENOTYPE | Lahl et al.
T cells in DT-treated DEREG mice compared with untreated 
DEREG mice or WT control mice (Fig. 3 A). A similar degree 
of depletion was observed in the thymus and in Peyer’s patches 
(Fig. 3 B and not depicted). The daily dose of 1 μg DT de-
pleted up to 90% of Foxp3+ T reg cells after 7 d. Importantly, 
DT treatment did not aff  ect other lymphocyte subsets (Fig. 3 
and not depicted), suggesting that DT treatment of DEREG 
mice allows for the selective depletion of Foxp3+ cells.
Selective depletion of T reg cells leads to an enhanced 
and prolonged delayed-type hypersensitivity (DTH) response
Previous attempts to analyze the role of CD4+ T reg cells in 
vivo have used anti-CD25 depleting antibodies (1). In those 
experiments, the antibodies remained in the circulation for 
a considerable time, and recent evidence has indicated that 
CD25+ eff  ector T cells are also aff  ected (unpublished data). 
In this report, we investigated whether selective depletion of 
Foxp3+ T reg cells in DEREG mice would provide a method 
to analyze the role of CD4+ T reg cells during an established 
immune response. We chose a DTH model in which T reg 
cells were depleted after hapten-specifi  c sensitization during 
the phase when CD25+   eff  ector T cells driving the DTH re-
sponse were generated (22).
Both untreated DEREG and WT control mice developed 
a weak DTH response after challenge with the hapten, as indi-
cated by footpad swelling. DT treatment resulted in a substan-
tially increased DTH response in DEREG mice 24, 48, and 
72 h after challenge, suggesting that Foxp3+ T reg cells are 
involved in the regulation of the local infl  ammatory response 
(Fig. 4 A and not depicted). The increased footpad swelling 
in DT-treated DEREG mice was accompanied by an in-
creased cellular immune response within the draining LN 
(Fig. S2,   available at http://www.jem.org/cgi/content/full/
jem.20061852/DC1). In contrast to the increased footpad 
swelling after DT treatment in DEREG mice, WT control mice 
receiving anti-CD25 antibodies showed a weak DTH response 
comparable to challenged mice without T reg cell depletion 
(Fig. 4 A). Analysis of CD4+ T cells from   peripheral blood be-
fore challenge revealed a very effi   cient depletion of both CD25+ 
and CD25−GFP+ T reg cells in DT-treated DEREG mice, 
whereas a suffi   cient fraction of CD25+GFP− cells remained 
(Fig. 4 B). Anti-CD25 antibody treatment completely removed 
CD25+ cells from circulation, suggesting that this treatment not 
only led to the depletion of CD25+CD4+ T reg cells but also 
removed CD25+ eff  ector T cells (Fig. 4 C). Additionally, the 
same treatment has recently been shown to effi   ciently deplete 
CD25+CD4+ T reg cells but not CD25−Foxp3+ T reg cells 
(23). Therefore, our data suggest that selective removal of total 
Foxp3+ T reg cells by the use of DEREG mice represents a 
major progress in the analysis of T reg cell function during the 
eff  ector phase of an ongoing immune response.
Neonatal depletion of Foxp3+ T reg cells leads 
to the development of scurfy-like symptoms
Lack of functional T reg cells has been suggested to cause the 
  fatal lymphoproliferative disease in scurfy mice. The DEREG 
mice described in this report have now allowed us to assess 
whether diminution of Foxp3+ T reg cells is suffi   cient to 
induce scurfy-like symptoms or whether dysfunctional T reg 
cells expressing the truncated Foxp3 protein contribute 
to pathology.
The scurfy mutation is manifested by several clinical dis-
orders and is evident primarily in the lymphoid organs and 
skin 14 d after birth (24). The disease is characterized by runting; 
scaliness and crusting of the eyelids, ears, and tail; gross inter-
nal lesions including marked splenomegaly; enlarged LNs; 
Figure 4.  Depletion of Foxp3+ cells in DEREG mice results in 
  enhanced DTH reaction. (A) Differences in thickness between challenged 
and PBS-injected footpads in the indicated groups of mice 24 h after 
challenge. Horizontal lines represent the means. (B) Flow cytometric 
analysis of CD25 and eGFP expression in live-gated peripheral blood 
CD4+ T cells after DT treatment of DEREG mice (before challenge) and 
in   untreated DEREG control mice reveals that, after depletion, most of 
the remaining CD25+CD4+ T cells are GFP negative. (C) Frequency of 
  peripheral blood CD25+CD4+ T cells before challenge. Plots show the 
absence of double-positive cells in mice that received 500 μg αCD25 and 
a reduction of CD25+CD4+ T cells in DEREG mice injected with 5 × 1 μg 
DT (bottom). Control groups show the normal frequency of CD25+CD4+ 
T cells (top). Cells were live gated. Data are representative of one out of 
three independent experiments with fi  ve mice per group. The percentage 
of cells in each quadrant (B and C) is indicated. JEM VOL. 204, January 22, 2007  61
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and severe anemia. These symptoms result in a wasting syn-
drome that generally leads to death by 15–24 d of age (24). 
When newborn DEREG mice were treated with 500 ng 
DT i.p. (or 100 ng DT s.c.) followed by a second DT injec-
tion on day 7, which led to an almost complete depletion 
of Foxp3+CD4+ T cells (Fig. S3, available at http://www
.jem.org/cgi/content/full/jem.20061852/DC1), these mice 
developed an aggressive lymphoproliferative auto  immune 
syndrome strongly resembling the observed patho  logy in 
scurfy mice. The spleens of DT-treated DEREG mice were 
signifi  cantly enlarged and resembled spleens from age-matched 
scurfy mice (Fig. 5 A). Histologically, they displayed a dis-
rupted architecture with hyperplasia of the white and red pulp 
(not depicted). DT-treated DEREG mice showed markedly 
enlarged LNs as well as increased total cell numbers when 
compared with both DT-treated WT control and scurfy mice 
(Fig. 5 B). Histological analysis of DT-treated DEREG mice 
revealed massive infl  ammatory  infi   ltrates in various organs 
(Fig. 5 C). The skin overlying the hyaline cartilage of the ear 
was extensively thickened with epidermal hyperplasia and a 
dense infi  ltrate of lymphocytes—including large numbers of 
CD3+ T cells (Fig. S4)—with admixed neutrophils and macro-
phages in the dermis compared with DT-treated WT control 
mice. The lungs of DT-treated DEREG mice showed similar 
infi  ltrates as scurfy mice with peribronchial and perivascular 
distribution when compared with the normal lung with thin 
and delicate alveolar walls in control mice. The acini of the 
pancreas displayed infi  ltrates with destruction of the islets 
(insulitis), and the liver exhibited portal aggregates (Fig. 5 C). 
Because lesions in DT-treated DEREG mice closely resem-
bled those observed in scurfy mice and no signifi  cant dif-
ferences in the pathology of those particular organs were 
ob  served, we concluded that diminution of CD4+ T reg cells 
is suffi     cient to induce the lethal lymphoproliferative auto-
immune syndrome and that an active contribution of patho-
genic autoreactive CD4+ T cells expressing the truncated Foxp3 
protein is not necessarily required (19). Indeed, immuno-
histochemical staining for Foxp3 showed that in the thymi 
and spleens of DT-treated DEREG mice the vast majority of 
Foxp3+ T reg cells were absent (Fig. 5 D and not depicted).
In contrast to depletion of Foxp3+ T reg cells by DT 
  injection, which consistently resulted in the development 
Figure 5.  Depletion of Foxp3+ cells in neonate DEREG mice 
  results in a scurfy-like phenotype. Neonates were injected i.p. 
on days 1 and 7 after birth with 500 ng DT and analyzed after 21 d. 
(A) Splenomegaly in scurfy mice (top) and depleted DEREG mice (middle) 
compared with a DT-injected WT littermate (bottom). (B) Enlargement 
and increase of LN cellularity (left, scapular LN; right, inguinal LN; the 
mean of total cell numbers from four pooled peripheral LN is shown) 
in scurfy and depleted DEREG mice compared with DT-treated WT 
  littermates. (C) Histological analysis of different organs. Figures show 
hematoxylin and eosin staining of the indicated organs in the different 
mice. Bar, 100 μm. (D) Foxp3 staining (brown) of thymus sections shows 
remaining Foxp3+ expression only in WT littermates. Data are represen-
tative of 1 out of 10 independently analyzed mice in which a total of 
12 organs each (spleen, LN, Peyer’s patches, thymus, liver, pancreas, 
  salivary gland, heart, lung, kidney, gastrointestinal tract, and skin) was 
evaluated. Bar, 50 μm.62  INDUCED SCURFY PHENOTYPE | Lahl et al.
of scurfy-like symptoms, T reg cell depletion in neonatal 
mice with anti-CD25 antibodies resulted in marginal devel-
opment of autoimmune disease, if at all (4, 5). These dis-
crepancies are again best elucidated by both the existence 
of CD25−Foxp3+ T reg cells, especially within peripheral 
tissues (1, 6, 7), as well as the induced expression of CD25 
on activated conventional CD4+ T cells, which are critically 
involved in the development of the scurfy phenotype (16). 
Interestingly, in adult mice neither T reg cell depletion with 
anti-CD25 antibodies (8) nor depletion of total Foxp3+ 
T reg cells by DT treatment (not depicted) resulted in the 
development of autoimmune diseases. This fi  nding can be 
explained by the lack of lymphopenia-induced proliferation 
preventing the activation of autoreactive T cells (5). Further-
more, within 2 wk after the last DT injection, we observed 
a signifi  cant rebound of Foxp3+ T reg cells in adult but 
not neonatal DEREG mice (Fig. 5 D; Fig. S5, available at 
http://www.jem.org/cgi/content/full/jem.20061852/DC1; 
and not depicted), which might participate in the control of 
pathogenic eff  ector cells.
In summary, the novel BAC-transgenic DEREG mouse 
is a new tool to analyze Foxp3+ T reg cells in vivo. The 
previous limitations of antibody-based depletion protocols 
will be avoided because Foxp3+ T reg cells can be selec-
tively depleted in DEREG mice at any time of the im-
mune response. Thus, the model will allow more precise 
insights into the role of T reg cells in tumors, autoimmune 
disease, transplantation, and infection models. Furthermore, 
de  pletion of Foxp3+ T reg cells in neonatal DEREG mice 
also shed some light on the cellular players involved in 
the development of the fatal lymphoproliferative disease 
in scurfy mice, because our data unequivocally show that 
  depletion of Foxp3+ cells is suffi   cient to induce a scurfy-
like phenotype.
MATERIALS AND METHODS
Mice. DEREG and WT C57BL/6 mice were bred at the animal facility of 
the Institut für Medizinische Mikrobiologie, Immunologie und Hygiene at 
the Technische Universität München. Scurfy mice (B6.Cg-Foxp3 sf/J) were 
purchased from Charles River Laboratories. All animal experiments were 
performed under specifi  c pathogen-free conditions and in accordance with 
institutional, state, and federal guidelines.
Generation of DEREG mice. Transgenic mice were generated using 
BAC technology, as previously described (25, 26), with the following 
modifi  cations. As a transgene, the coding sequence of the DTR-eGFP fu-
sion protein was used (27). The BAC encoding the complete mouse foxp3 
gene locus (RP23-267C15) was obtained from the BACPAC Resources Cen-
ter at Children’s Hospital Oakland Research Institute. In contrast to the 
published overlap PCR strategy (26), homologous regions named Box A 
and Box B were ligated to DTR-eGFP via AscI (Box A) or PmeI sites 
(Box B). The polyA fragment was amplifi  ed from the TOPO Tools SV40 
pA 3′ element kit (Promega) using primers, adding a SpeI site 5′ and a 
PmeI site 3′. The WT BAC was recombined using the pLD53.SC1 shuttle 
vector provided by N. Heintz (The Rockefeller University, New York, 
NY), gel purifi  ed, and injected into the pronuclei of fertilized C57BL/6 
oocytes. Two transgenic mouse lines with high transgene expression were 
established (nos. 16.1 and 23.2). DEREG mice were genotyped by PCR us-
ing the primers P442 (5′-C  C  C  A  G  G  T  T  A  C  C  A  T  G  G  A  G  A  G  A  -3′) and P443 
(5′-G  A  A  C  T  T  C  A  G  G  G  T  C  A  G  C  T  T  G  C  -3′).
Antibodies, staining, and sorting reagents. The following antibodies 
and secondary reagents were purchased from eBioscience: αCD4 (H129.19), 
αCD25 (PC61), αCD8 (53–6.7), αB220 (RA3-6B2), αTCR-β (H57-597), 
αCD11c (HL3), αCD3ε (500A2), αB220 (RA3-6B2), αFoxp3 (FJK-16s), 
a T reg cell staining kit, streptavidin, and appropriate isotype controls. Rabbit 
αGFP and FITC-conjugated goat α rabbit polyclonal antibodies were ob-
tained from Invitrogen. The antibody αCD25 (PC61) was produced in our 
laboratory. For immunohistochemistry, the polyclonal αCD3 obtained from 
DakoCytomation was used.
Flow cytometry. Cytometric analysis was performed using a CyAn (Dako-
Cytomation) or a FACSCalibur (BD Biosciences) and FlowJo software (Tree 
Star, Inc.). Dead cells were excluded by propidium iodide staining or ethid-
ium monoazide (Sigma-Aldrich). Intracellular Foxp3 staining was performed 
with the PE α mouse Foxp3 staining set (Bioscience), according to the 
  manufacturer’s instructions.
Depletion of T reg cells. To deplete T reg cells, DEREG mice were in-
jected with DT (Merck) diluted in endotoxin-free PBS. In our standard 
protocol, 1 μg DT was injected i.p. on a daily basis for four to six consecu-
tive days unless otherwise indicated. Newborn mice were injected twice 
either i.p. with 500 ng or s.c. with 100 ng at days 1 and 7 after birth. Anti-
CD25 (PC61) was administered i.p. at 500 μg/mouse.
Microscopy, immunofl  uorescence staining, histology, and immuno-
histochemistry. LNs and spleens from scurfy and DT-treated mice were 
photographed individually with the same magnifi  cation using a stereo micro-
scope (MZ-APO; Leica). Immunofl   uorescent stainings were performed 
as previously described (28). Slides were examined under a fl  uorescence 
microscope (AxioImager M1; Carl Zeiss MicroImaging, Inc.) equipped 
with a CCD camera (AxioCam MRm; Carl Zeiss MicroImaging, Inc.) 
and processed with Axiovision software (Carl Zeiss MicroImaging, Inc.). 
Hematoxylin and eosin stainings were performed on formalin-fi  xed and 
paraffi     n-embedded organs. Foxp3 and CD3 immunohistochemistry was 
performed as previously described (29).
DTH model. DTH reactions were performed as previously described using 
2% and 0.1% NP-O-Su (Biosearch Technologies) for sensitization and chal-
lenge, respectively (30). For depletion of T reg cells, mice were injected i.p. 
with 1 μg DT per mouse for fi  ve consecutive days, starting on day 2 after 
sensitization. Alternatively, CD25-expressing cells were depleted via i.p. 
  injection of 500 μg anti-CD25 (PC61) on day 5 after sensitization. Mice 
were challenged on day 7 after sensitization, and the infl  ammatory response 
was determined 24 h later by the measurement of footpad thickness. For in vitro 
restimulation, mice were killed 48 h after challenge. 4 × 105 cells from drain-
ing popliteal and inguinal versus control LNs were stimulated with 3 × 105 
modifi  ed bone marrow GM-CSF–cultured DCs from naive mice. For modi-
fi  cation, DCs were incubated for 3 min at 37°C with 0.02% NP-O-Su. After 
4 d, proliferation and IFN-γ production were measured using the CellTiter-Glo 
Luminescent Cell Viability Assay (Promega) and the DuoSet ELISA (R&D 
Systems), according to the manufacturer’s instructions, respectively.
Online supplemental material. In Fig. S1, fl  ow cytometry analysis reveals 
that DTR-eGFP expression in DEREG mice is confi  ned to TCRβ+ T cells 
and precluded from B220+, CD11c+, and CD8+ cells. Fig. S2 depicts the 
increased cellular immune response in the local draining LN after DT treat-
ment in hapten-challenged mice. Fig. S3 depicts the degree of depletion 
of Foxp3+ T reg cells on day 8 in neonatal DEREG mice upon the second 
DT treatment on day 7. Fig. S4 shows CD3+ T cell infi  ltrates in diff  erent 
organs of DT-treated DEREG mice compared with scurfy and DT-treated 
WT control mice. Fig. S5 shows the rebound of Foxp3+ T reg cells in 
DT-treated DEREG mice. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20061852/DC1.
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